Ann: Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment, page-65

....and I don't understand why any Physician would condone Remdesivir after the fuller and unimpressive results just announced, or why the stock is up 8%.

Well I do really, which is why I am long Gilead despite having little faith in the efficacy of its results, before and after today's results. It will be tragedy if it is approved as anything other than an emergency treatment by the FDA due to political pressure. If it becomes the standard treatment a lot of people will die unnecessarily. Look at the results today. Look at the Ebola trials effects. Look at the Chinese study. This is a poor treatment choice. Sadly, the poor efficacy of this drug probably improves MSB's prospects to yesterday given the mess in will leave in its wake.

No-one is saying Remetemcel-L is a sure thing, but based on analysis of the biology of the virus, illnesses involved, the way Remestemcel-L works and the results of trials in the past and more recently, it is one of the best prospects out there. Having also had tenocyte stem-cells (OCC) for a botched bicep surgery, I am doing my best to keep rational on this one, but to me this treatment works. The stock market will do what it does, hence this stock has a $1.02-$4.45 YTD range.

If I am on your ward Doc' I'd be refusing Remdesivir and pleading with you to get me on MSB's trial with my weakening breath.